Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2011. The report details a specific share repurchase transaction executed on August 5, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 2,200,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,295.5 pence per share; lowest price paid was 1,263.5 pence per share.
- Treasury Holdings (Settled): 499,596,816 shares (8.91% of total issued share capital).
- Treasury Holdings (Including Unsettled): 502,996,816 shares (9.85% of total voting rights).
- Shares in Issue: 5,105,647,919 shares (excluding treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding share capital through the purchase and subsequent cancellation of 2,200,000 shares. This action increased the proportion of shares held in Treasury to 9.85% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding share repurchases.
Investor Verification Points
- Confirm the total cost of the 2,200,000 shares purchased based on the weighted average price between 1,263.5 and 1,295.5 pence.
- Verify the updated total issued share capital after the cancellation of the repurchased shares.
- Check subsequent filings to confirm the settlement of the 3,400,000 shares (difference between settled and total treasury holdings) mentioned as not yet settled.